StemCell Institute Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022
Revenue	2,811	2,679	2,481	2,091	1,781
Revenue Growth (YoY)	4.93%	7.98%	18.65%	17.41%	26.40%
Cost of Revenue	1,099	987	905	755	670
Gross Profit	1,712	1,692	1,576	1,336	1,111
Selling, General & Admin	1,509	1,250	1,142	1,024	874
Operating Expenses	1,509	1,273	1,162	1,038	884
Operating Income	203	419	414	298	227
Interest Expense	-5	-1	-	-	-
Interest & Investment Income	20	10	3	1	-
Other Non Operating Income (Expenses)	-1	-	-1	-	-16
EBT Excluding Unusual Items	217	428	416	299	211
Gain (Loss) on Sale of Investments	-	136	22	-	-
Other Unusual Items	-	-	2	-21	-
Pretax Income	217	564	440	278	211
Income Tax Expense	86	179	130	80	78
Earnings From Continuing Operations	131	385	310	198	133
Minority Interest in Earnings	24	-	-	-	-
Net Income	155	385	310	198	133
Net Income to Common	155	385	310	198	133
Net Income Growth	-59.74%	24.19%	56.57%	48.87%	114.52%
Shares Outstanding (Basic)	10	10	10	10	5
Shares Outstanding (Diluted)	10	10	10	10	5
Shares Change (YoY)	-1.39%	-0.05%	-	102.33%	4.05%
EPS (Basic)	15.35	37.59	30.25	19.32	26.26
EPS (Diluted)	15.35	37.59	30.25	19.32	26.26
EPS Growth	-59.17%	24.25%	56.57%	-26.42%	106.16%
Free Cash Flow	-336	-11	151	43	288
Free Cash Flow Per Share	-33.27	-1.07	14.74	4.20	56.87
Gross Margin	60.90%	63.16%	63.52%	63.89%	62.38%
Operating Margin	7.22%	15.64%	16.69%	14.25%	12.75%
Profit Margin	5.51%	14.37%	12.50%	9.47%	7.47%
Free Cash Flow Margin	-11.95%	-0.41%	6.09%	2.06%	16.17%
EBITDA	359	547	534	402	323
EBITDA Margin	12.77%	20.42%	21.52%	19.23%	18.14%
D&A For EBITDA	156	128	120	104	96
EBIT	203	419	414	298	227
EBIT Margin	7.22%	15.64%	16.69%	14.25%	12.75%
Effective Tax Rate	39.63%	31.74%	29.54%	28.78%	36.97%
Advertising Expenses	-	221	196	194	175